RAD51C

Across TCGA pan-cancer cohorts, RAD51C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD51C data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher RAD51C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAD51C expression acts as an unfavorable survival marker.

THYM, STAD, and PRAD are the cancer types where RAD51C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
STAD	OS	Median	All	0.237	0.691	<.001	39	view →
PRAD	OS	Median	All	0.157	0.883	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	OS	Median	All	0.527	0.872	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD51C–THYM (OS)

Open the THYM breakdown →